ALCAM/CD166 is up‐regulated in low‐grade prostate cancer and progressively lost in high‐grade lesions
The DOI matches its Crossref record.
Abstract
BACKGROUND: Activated leukocyte cell adhesion molecule (ALCAM, CD166) is expressed in various tissues, including malignant melanoma, prostate cancer cell lines, and prostate cancer. We aimed to clarify the expression patterns of ALCAM in normal and malignant prostate tissue. METHODS: RNA from 54 matched pairs of microdissected prostate tissue (tumor and normal) was hybridized to a custom built 4K GeneChip. Frozen section immunohistochemistry was used to confirm the ALCAM expression. RESULTS: Chip‐based transcript analysis revealed an up‐regulation of ALCAM in prostate cancer in 22% of cases. Immunohistochemistry showed a focally raised ALCAM expression in 81% and a decreased expression in 19% of cases. These expression patterns correlated significantly with Gleason tumor grade: ALCAM up‐regulation was found in most low‐grade tumors (Gleason grade 1–3), whereas down‐regulation occurred preferentially in high‐grade tumors (Gleason grade 4 and 5), although up‐regulation of ALCAM expression was preserved in two Gleason grade 5 tumors. CONCLUSION: ALCAM expression is commonly disturbed in prostate cancer, which might indicate a role of ALCAM in the progression of this disease. Prostate 54: 34–43, 2003. © 2002 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Wissmann, C., Wild, P. J., Kaiser, S., Roepcke, S., Stoehr, R., Woenckhaus, M., Kristiansen, G., Hsieh, J., Hofstaedter, F., Hartmann, A., et al. (2003) · The Journal of Pathology · doi:10.1002/path.1449 · Cited by 333
Self-citationLugli, A., Iezzi, G., Hostettler, I., Muraro, M. G., Mele, V, Tornillo, L., Carafa, V, Spagnoli, G., Terracciano, L., & Zlobec, I. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605762 · Cited by 313
ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival
Weichert, W., Knösel, T., Bellach, J., Dietel, M., & Kristiansen, G. (2004) · Journal of Clinical Pathology · doi:10.1136/jcp.2004.016238 · Cited by 264
Self-citationMass Spectrometric Detection of Tissue Proteins in Plasma
Zhang, H., Liu, A. Y., Loriaux, P., Wollscheid, B., Zhou, Y., Watts, J. D., & Aebersold, R. (2007) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m600160-mcp200 · Cited by 180
Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer
Su, Y., Liu, Y., Behrens, C. R., Bidlingmaier, S., Lee, N.-K., Aggarwal, R., Sherbenou, D. W., Burlingame, A. L., Hann, B. C., Simko, J. P., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.121497 · Cited by 82
“However, if these antigens are not required for tumor survival, they may be lost during disease progression and heterogeneously expressed in late-stage cancers (16–18).”
Background
Metadata
- Authors
- Kristiansen, G., Pilarsky, C., Wissmann, C., Stephan, C., Weissbach, L., Loy, V., Loening, S., Dietel, M., & Rosenthal, A.
- Venue
- The Prostate
- Publisher
- Wiley
- Published
- 2002-12-12
- Volume
- 54
- Issue
- 1
- Pages
- 34-43
- ISSN
- 0270-4137 (ISSN-L)
- 1097-0045
- OpenAlex
- W2129049215
- Cited by
- 136
- References
- 0
- FWCI
- 4.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: ALCAM/CD166 is up‐regulated in low‐grade prostate cancer and progressively lost in high‐grade lesions. https://app.cochat.ai/papers/10.1002/pros.10161
- The paper
- Kristiansen, G., Pilarsky, C., Wissmann, C., Stephan, C., Weissbach, L., Loy, V., Loening, S., Dietel, M., & Rosenthal, A. (2003). ALCAM/CD166 is up‐regulated in low‐grade prostate cancer and progressively lost in high‐grade lesions. The Prostate. https://doi.org/10.1002/pros.10161
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.